Shilpa announced a $50 million expansion of its peptide manufacturing facility in Raichur, India, citing increased demand for peptide-based therapies including GLP-1s. The planned buildout includes up to 1,000-liter reactor capacity, export-oriented operations, and GMP-aligned purification capabilities. The company positioned the move as meeting both high-volume GLP-1 program needs and higher-complexity chemistry for next-generation peptide drugs and conjugates. The investment also signals continuing downstream tightening of peptide manufacturing capacity as GLP-1 demand remains a key utilization driver. For the broader industry, new CDMO capacity can influence supply timelines for drug substance and help determine whether developers can scale clinical candidates without manufacturing bottlenecks.